LYMPHOMAS

Treatment options are limited for patients with Waldenstrom's macroglobulinemia (WM), says Morie A. Gertz, MD. Combination therapies offer a potential solution, but the rarity of the disease is an obstacle.

The FDA has granted an accelerated approval to nivolumab for patients with classical Hodgkin lymphoma following relapse or progression after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma (cHL), giving the drug the potential to become the first PD-1 inhibitor approved for a hematologic malignancy.

Expanding on the efficacy shown in numerous single-group studies, a phase II study published in The Lancet Oncology showed lenalidomide significantly increased progression free survivalin patients with relapsed or refractory mantle cell lymphoma.

Six ongoing clinical trials investigating several idelalisib (Zydelig) combinations have been halted due to reports of increased adverse events such as death for patients with hematologic malignancies, according to an alert issued by the FDA.

Obinutuzumab (Gazyva) plus bendamustine, followed by obinutuzumab alone has been approved by the FDA as a treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

In this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.

​John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.

Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.

Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.

Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).

Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).

In this review, our authors discuss the mechanism of action and clinical development of various checkpoint inhibitors in lymphoma.

Ibrutinib (Imbruvica) saw over 80% response in patients with treatment-refractory Waldenstrom

Two CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies showed complete response (CR) rates from 90% to 100% in patients with high-risk acute lymphoblastic leukemia (ALL), according to data from two studies presented during the 2015 ASH Annual Meeting.

Updated data shows chimeric antigen receptor (CAR)-modified T-cell therapies continue to remain effective for patients with non-Hodgkin lymphoma (NHL), according to findings presented at the 2015 ASH Annual Meeting.

Ibrutinib reduced risk of death by 84% against chlorambucil in treatment-naive elderly patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma.

Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease

Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).

When John P. Leonard, MD, spoke at the American Society of Hematology inaugural meeting on Hematologic Malignancies about mantle cell lymphoma (MCL), he balanced his enthusiasm about the emerging benefits that tumor profiling brings to this disease with an acknowledgement that many important questions about mantle cell lymphoma remain unanswered.

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

The therapeutic palette for Hodgkin Lymphoma is growing, along with improvements in survival and cure rates.

The antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) was recently approved by the FDA as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients who have Hodgkin lymphoma and are at risk of relapse or progression.

The development of novel targeted drugs, such as brentuximab vedotin (Adcentris), against discrete cell surface proteins, such as CD30, has awakened a new way of thinking about targeted cancer biology